AcelRx to resubmit NDA in 2015

AcelRx Pharmaceuticals Inc. (Nasdaq: ACRX) will resubmit its New Drug Application for Zalviso in the first quarter of 2015. The stock price tumbled $1.23 to $5.49.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.